169 related articles for article (PubMed ID: 37305292)
21. Discovery of potent antiproliferative agents from selected oxygen heterocycles as EGFR tyrosine kinase inhibitors from the U.S. National Cancer Institute database by in silico screening and bioactivity evaluation.
Jiwacharoenchai N; Saruengkhanphasit R; Niwetmarin W; Seetaha S; Choowongkomon K; Ruchirawat S; Eurtivong C
Bioorg Med Chem Lett; 2022 Feb; 58():128524. PubMed ID: 34995690
[TBL] [Abstract][Full Text] [Related]
22. Design, synthesis and anticancer evaluation of 1H-pyrazolo[3,4-d]pyrimidine derivatives as potent EGFR
Gaber AA; Bayoumi AH; El-Morsy AM; Sherbiny FF; Mehany ABM; Eissa IH
Bioorg Chem; 2018 Oct; 80():375-395. PubMed ID: 29986185
[TBL] [Abstract][Full Text] [Related]
23. EGFR tyrosine kinase targeted compounds: in vitro antitumor activity and molecular modeling studies of new benzothiazole and pyrimido[2,1-b]benzothiazole derivatives.
Gabr MT; El-Gohary NS; El-Bendary ER; El-Kerdawy MM
EXCLI J; 2014; 13():573-85. PubMed ID: 26417284
[TBL] [Abstract][Full Text] [Related]
24. Novel scaffold hopping of potent benzothiazole and isatin analogues linked to 1,2,3-triazole fragment that mimic quinazoline epidermal growth factor receptor inhibitors: Synthesis, antitumor and mechanistic analyses.
Rezki N; Almehmadi MA; Ihmaid S; Shehata AM; Omar AM; Ahmed HEA; Aouad MR
Bioorg Chem; 2020 Oct; 103():104133. PubMed ID: 32745759
[TBL] [Abstract][Full Text] [Related]
25. Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence.
Wang X; Goldstein D; Crowe PJ; Yang JL
Onco Targets Ther; 2016; 9():5461-73. PubMed ID: 27660463
[TBL] [Abstract][Full Text] [Related]
26. Novel 4-arylaminoquinazolines bearing
Zhang Y; Chen L; Li X; Gao L; Hao Y; Li B; Yan Y
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1668-1677. PubMed ID: 31530043
[TBL] [Abstract][Full Text] [Related]
27. Novel quinoline-3-carboxamides (Part 2): Design, optimization and synthesis of quinoline based scaffold as EGFR inhibitors with potent anticancer activity.
Aly RM; Serya RAT; El-Motwally AM; Esmat A; Abbas S; Abou El Ella DA
Bioorg Chem; 2017 Dec; 75():368-392. PubMed ID: 29096097
[TBL] [Abstract][Full Text] [Related]
28. Synthesis, Molecular Dynamics Simulation, and
Nili Ahmadabadi M; Rezaee E; Nematpour M; Karami L; Mokhtari S; Kobarfard F; Tabatabai SA
Iran J Pharm Res; 2022 Dec; 21(1):e133840. PubMed ID: 36915409
[TBL] [Abstract][Full Text] [Related]
29. Novel 2-(5-Aryl-4,5-Dihydropyrazol-1-yl)thiazol-4-One as EGFR Inhibitors: Synthesis, Biological Assessment and Molecular Docking Insights.
Al-Warhi T; El Kerdawy AM; Said MA; Albohy A; Elsayed ZM; Aljaeed N; Elkaeed EB; Eldehna WM; Abdel-Aziz HA; Abdelmoaz MA
Drug Des Devel Ther; 2022; 16():1457-1471. PubMed ID: 35607598
[TBL] [Abstract][Full Text] [Related]
30. The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor.
Godin-Heymann N; Ulkus L; Brannigan BW; McDermott U; Lamb J; Maheswaran S; Settleman J; Haber DA
Mol Cancer Ther; 2008 Apr; 7(4):874-9. PubMed ID: 18413800
[TBL] [Abstract][Full Text] [Related]
31. Discovery of novel JAK2 and EGFR inhibitors from a series of thiazole-based chalcone derivatives.
Sanachai K; Aiebchun T; Mahalapbutr P; Seetaha S; Tabtimmai L; Maitarad P; Xenikakis I; Geronikaki A; Choowongkomon K; Rungrotmongkol T
RSC Med Chem; 2021 Mar; 12(3):430-438. PubMed ID: 34046625
[TBL] [Abstract][Full Text] [Related]
32. Transtinib, a potent tyrosine kinase inhibitor inhibits L858R/T790M mutant NSCLC cell lines and xenografts.
Hu P; Han DX; Ruan RS; Zheng LM; Chou SH; Tzeng CM
Oncotarget; 2016 Jun; 7(24):35741-35752. PubMed ID: 26848869
[TBL] [Abstract][Full Text] [Related]
33. Design, Synthesis, and Antiproliferative Activity of New 5-Chloro-indole-2-carboxylate and Pyrrolo[3,4-
Al-Wahaibi LH; Mohammed AF; Abdelrahman MH; Trembleau L; Youssif BGM
Molecules; 2023 Jan; 28(3):. PubMed ID: 36770936
[TBL] [Abstract][Full Text] [Related]
34. Discovery of novel 2,4-diarylaminopyrimidine derivatives as potent and selective epidermal growth factor receptor (EGFR) inhibitors against L858R/T790M resistance mutation.
Yan Q; Chen Y; Tang B; Xiao Q; Qu R; Tong L; Liu J; Ding J; Chen Y; Ding N; Tan W; Xie H; Li Y
Eur J Med Chem; 2018 May; 152():298-306. PubMed ID: 29730192
[TBL] [Abstract][Full Text] [Related]
35. Monitoring of gefitinib sensitivity with radioiodinated PHY based on EGFR expression.
Yoshimoto M; Hirata M; Kanai Y; Naka S; Nishii R; Kagawa S; Kawai K; Ohmomo Y
Biol Pharm Bull; 2014; 37(3):355-60. PubMed ID: 24583857
[TBL] [Abstract][Full Text] [Related]
36. Design, Synthesis, Molecular Docking, and Anticancer Evaluation of Pyrazole Linked Pyrazoline Derivatives with Carbothioamide Tail as EGFR Kinase Inhibitors.
Nawaz F; Alam O; Perwez A; Rizvi MA; Naim MJ; Siddiqui N; Firdaus JU; Rahman S; Jha M; Sheikh AA
Anticancer Agents Med Chem; 2021; 21(1):42-60. PubMed ID: 32718297
[TBL] [Abstract][Full Text] [Related]
37. Discovery of Anilino-1,4-naphthoquinones as Potent EGFR Tyrosine Kinase Inhibitors: Synthesis, Biological Evaluation, and Comprehensive Molecular Modeling.
Mahalapbutr P; Leechaisit R; Thongnum A; Todsaporn D; Prachayasittikul V; Rungrotmongkol T; Prachayasittikul S; Ruchirawat S; Prachayasittikul V; Pingaew R
ACS Omega; 2022 May; 7(21):17881-17893. PubMed ID: 35664590
[TBL] [Abstract][Full Text] [Related]
38. A New Series of Indeno[1,2-
Özdemir A; Ciftci H; Sever B; Tateishi H; Otsuka M; Fujita M; Altıntop MD
Molecules; 2022 Jan; 27(2):. PubMed ID: 35056800
[TBL] [Abstract][Full Text] [Related]
39. New Anticancer Theobromine Derivative Targeting EGFR
Elkaeed EB; Yousef RG; Elkady H; Alsfouk AA; Husein DZ; Ibrahim IM; Metwaly AM; Eissa IH
Molecules; 2022 Sep; 27(18):. PubMed ID: 36144596
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
